What is Galapagos N.V.'s Shariah compliance score?

Galapagos N.V.'s (GLPG) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Galapagos N.V. pass AAOIFI screening?

Galapagos N.V. (GLPG) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (GLPG: 0.4%), (3) interest-bearing deposits below 30% (GLPG: 162.5%), and (4) prohibited income below 5% (GLPG: 4.2%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Galapagos N.V. stock?

Galapagos N.V. (GLPG) has a non-permissible income ratio of 4.17%. Muslim investors should purify this percentage of any dividends received and capital gains realized from GLPG shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Galapagos N.V. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Galapagos N.V. (GLPG) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about GLPG's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Galapagos N.V. (GLPG) halal? Not Halal. Based on AAOIFI screening, Galapagos N.V. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

GLPG: Is Galapagos N.V. Halal?

Not Halal

Galapagos N.V.

NASDAQHealthcareBE

$27.98

+1.71%

AvoidBorderlineClean

About Galapagos N.V.

Galapagos NV functions as an integrated biopharmaceutical enterprise, concentrating its efforts on identifying, developing, and marketing a diverse range of medications aimed at critical unaddressed medical conditions. The company's comprehensive pipeline includes several significant experimental therapies. Leading this portfolio is filgotinib, a JAK1 inhibitor that is currently progressing through various clinical trial phases for the management of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel Crohn's disease, fistulizing Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and uveitis. Additionally, their developmental assets feature GLPG1972, which has successfully completed its Phase 2b trial for osteoarthritis. A series of "Toledo" compounds, namely GLPG3970, GLPG4399, and GLPG4876, are in development for inflammatory conditions. GLPG4716 and Ziritaxestat are also part of the pipeline, targeting idiopathic pulmonary fibrosis. Further pipeline advancements include GLPG2737, a cystic fibrosis transmembrane conductance regulator undergoing Phase 2 clinical trials for patients afflicted with autosomal dominant polycystic kidney disease. Another JAK1 inhibitor, GLPG0555, is in Phase 1b development for osteoarthritis. Galapagos NV has established collaborative agreements with major industry players such as Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. The company was established in 1999 and its headquarters are located in Mechelen, Belgium.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 12, 2026

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap0.4% / 30.0%

Compliance History

Not Halal, unchanged since Jun 2026.

No status changes recorded since we began tracking.

Tracked since Jun 2026. Updates automatically on each re-screen.

Screened: Jun 12, 2026Fiscal: FY 2025Source: FMP

Financial Overview

Market Cap

1.8B

Price

$27.98

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track GLPG and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Galapagos N.V. (GLPG) halal to invest in?

Galapagos N.V. (GLPG) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Galapagos N.V. get a F compliance rating?

Galapagos N.V. (GLPG) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.4% (limit 30%); interest-bearing deposits of 162.5% (limit 30%); prohibited income of 4.17% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Galapagos N.V.'s Shariah verdict?

Galapagos N.V.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Galapagos N.V. re-screened for Shariah compliance?

Galapagos N.V. (GLPG) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 12, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.